SynthesisFrontiers in medicine2025
Emodin for pulmonary fibrosis: a systematic review and meta-analysis of efficacy and molecular mechanisms.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and meta-analysis aimed to evaluate emodin's therapeutic efficacy in animal models of pulmonary fibrosis (PF) and summarize its anti-fibrotic mechanisms, providing a theoretical basis for the application of emodin in the clinical treatment of fibrosis. Methods: A comprehensive literature search was conducted across 4 major international databases and 4 Chinese databases through July 2025. Study quality was assessed using the SYRCLE risk of bias tool. The mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CIs) was used to evaluate emodin's effects on fibrosis severity, histopathological damage, inflammation, oxidative stress, and epithelial-mesenchymal transition (EMT). Results: Meta-analysis revealed emodin significantly attenuated PF across multiple scales [Szapiel score: SMD = -1.73, 95% CI: -2.02 to -1.43; Ashcroft score: SMD = -3.10, 95% CI: -4.40 to -1.79; fibrotic area: SMD = -4.97, 95% CI: -7.87 to -2.08]. Emodin substantially reduced hydroxyproline content (SMD = -1.91, 95% CI: -2.42 to -1.41) and collagen deposition, while improving alveolitis (SMD = -1.89, 95% CI: -2.21 to -1.57) and lung coefficients (SMD = -1.35, 95% CI: -2.06 to -0.65). Emodin also mitigated inflammation by reducing pulmonary levels of IL-6 (SMD = -3.86, 95% CI: -6.21 to -1.51), IL-1β (SMD = -3.21, 95% CI: -4.90 to -1.53), and TNF- Conclusion: Emodin effectively alleviates PF through reducing collagen deposition, attenuating inflammation, suppressing oxidative stress, and inhibiting EMT. Subgroup analyses indicated that heterogeneity across studies was partly attributable to variations in dosing regimens and animal species. Further investigation into the anti-fibrotic properties of emodin is warranted to facilitate its therapeutic development. Systematic review registration: CRD420251131483, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251131483.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.